MX346950B - Reovirus que tienen secuencias modificadas. - Google Patents

Reovirus que tienen secuencias modificadas.

Info

Publication number
MX346950B
MX346950B MX2013013938A MX2013013938A MX346950B MX 346950 B MX346950 B MX 346950B MX 2013013938 A MX2013013938 A MX 2013013938A MX 2013013938 A MX2013013938 A MX 2013013938A MX 346950 B MX346950 B MX 346950B
Authority
MX
Mexico
Prior art keywords
reoviruses
modified
modified sequences
nucleic acid
well
Prior art date
Application number
MX2013013938A
Other languages
English (en)
Inventor
C Coffey Matthew
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346950(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX346950B publication Critical patent/MX346950B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un reovirus aislado caracterizado porque comprende uno o más de los siguientes polipéptidos: a) un polipéptido sigma-3 que comprende la SEQ ID NO: 15, b) un polipéptido mu-1 que tiene al menos una modificación de aminoácidos, en donde al menos una modificación de aminoácidos comprende una Asp en el residuo 73 enumerado en relación con la SEQ ID NO: 27 (No. De Acceso al GenBank M20161.1); o c) un polipéptido mu-2 que tiene al menos una modificación de aminoácidos, en donde al menos una modificación de aminoácidos comprende una Ser en el residuo 528 enumerada en relación con la SEQ ID NO: 29 (No. De Acceso al GenBank AF461684.1). .
MX2013013938A 2007-03-12 2009-09-08 Reovirus que tienen secuencias modificadas. MX346950B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US98956807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
MX346950B true MX346950B (es) 2017-04-06

Family

ID=39758956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009009598A MX2009009598A (es) 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas.
MX2013013938A MX346950B (es) 2007-03-12 2009-09-08 Reovirus que tienen secuencias modificadas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009009598A MX2009009598A (es) 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas.

Country Status (17)

Country Link
US (5) US7803385B2 (es)
EP (2) EP2132315B1 (es)
JP (1) JP5577103B2 (es)
KR (1) KR101647843B1 (es)
CN (1) CN103710359A (es)
AR (1) AR066395A1 (es)
AU (1) AU2008226291B2 (es)
CA (1) CA2678721C (es)
DK (1) DK2132315T3 (es)
ES (1) ES2548442T3 (es)
HK (1) HK1132761A1 (es)
IL (4) IL200353A (es)
MX (2) MX2009009598A (es)
SG (1) SG191602A1 (es)
TW (1) TW200904979A (es)
WO (1) WO2008110004A1 (es)
ZA (1) ZA200905951B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP2132315B1 (en) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
EP2296679A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
BRPI0910185A2 (pt) * 2008-06-26 2015-12-01 Ceva Sante Animale S A sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
US9395356B2 (en) 2009-10-02 2016-07-19 The National Veterinary Institute Piscine reovirus immunogenic compositions
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2022139490A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도
WO2023048532A1 (ko) * 2021-09-24 2023-03-30 바이로큐어 주식회사 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DE60142485D1 (de) 2000-11-09 2010-08-12 Oncolytics Biotech Inc Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen
CA2430495A1 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
CA2437962C (en) * 2001-03-16 2005-11-15 Oncolytics Biotech Inc. Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2571844A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
US10260049B2 (en) * 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
EP2132315B1 (en) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
EP2296679A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY
TW201233803A (en) * 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤

Also Published As

Publication number Publication date
SG191602A1 (en) 2013-07-31
ZA200905951B (en) 2010-11-24
AU2008226291B2 (en) 2014-01-16
MX2009009598A (es) 2009-09-21
IL221700A0 (en) 2012-10-31
IL221702A0 (en) 2012-10-31
US20140186301A1 (en) 2014-07-03
US10039827B2 (en) 2018-08-07
CA2678721A1 (en) 2008-09-18
EP2952583A1 (en) 2015-12-09
AU2008226291A1 (en) 2008-09-18
EP2132315A1 (en) 2009-12-16
EP2132315A4 (en) 2011-10-05
US10596260B2 (en) 2020-03-24
KR101647843B1 (ko) 2016-08-11
WO2008110004A1 (en) 2008-09-18
CA2678721C (en) 2018-02-13
US20180344853A1 (en) 2018-12-06
JP5577103B2 (ja) 2014-08-20
CN103710359A (zh) 2014-04-09
DK2132315T3 (en) 2015-10-19
US8691241B2 (en) 2014-04-08
US7803385B2 (en) 2010-09-28
EP2132315B1 (en) 2015-07-15
AR066395A1 (es) 2009-08-19
US20080226602A1 (en) 2008-09-18
ES2548442T3 (es) 2015-10-16
US20110020288A1 (en) 2011-01-27
AU2008226291A2 (en) 2009-10-08
HK1132761A1 (en) 2010-03-05
KR20090125103A (ko) 2009-12-03
IL200353A0 (en) 2011-08-01
US11246930B2 (en) 2022-02-15
JP2010520758A (ja) 2010-06-17
IL200353A (en) 2017-07-31
US20090035278A2 (en) 2009-02-05
IL221701A0 (en) 2012-10-31
US20200237917A1 (en) 2020-07-30
TW200904979A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
MX346950B (es) Reovirus que tienen secuencias modificadas.
TN2009000291A1 (en) Inhibitors of mek
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2010004374A (es) Armazones proteinicos.
JO2778B1 (en) Certain vehicles, installations and methods
NO20090596L (no) Antivirale fosfinatforbindelser
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
TW200732349A (en) Anti-OX40L antibodies and methods using same
UA97502C2 (ru) Кристаллическая твердая основа разагилина
PH12013502230A1 (en) Multispecific antibodies
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX340993B (es) Agentes de suministro de acido fenilalquilcarboxilico.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof